Glaukos (NYSE:GKOS) today said it completed its acquisition of Glaukos for an undisclosed amount.
Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus.
Get the full story on our sister site, Drug Delivery Business.